Logical Therapeutics gains $30M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Ception Therapeutics
|
$14.7M
|
Third Point and Greenlight Capital |
The company's pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. |
|
Logical Therapeutics
|
$30M
|
SV Life Sciences |
The funding will allow Logical to advance multiple drug candidates, including its lead drug, LT-NS001, a naproxen pro-drug, through proof-of-concept clinical trials. |